Sandifer syndrome (see also ALTE)
Sandifer syndrome is the association of torsional dystonia, mainly involving the neck and upper extremities, with either esophageal reflux or hiatus hernia. Often, pediatric neurologists are the first to see patients with Sandifer syndrome because the primary care provider thinks that spasms represent seizures. Few reports of this syndrome exist; however, pediatric neurologists and gastroenterologists see patients with this complex not infrequently. The syndrome is most likely underrecognized. Sandifer syndrome is thought to result in enhanced esophageal clearance of refluxed material.
Incidence is unknown, although some suggestion indicates that in clinical practice it occurs in less than 1% of children with gastroesophageal reflux.
Age: Typically, Sandifer syndrome is observed from infancy to early childhood. Children with severe mental impairment may experience Sandifer syndrome into adolescence.
History: Sandifer syndrome is most commonly mistaken for seizures. The child typically appears to have an alteration in mental status associated with the tonic posturing.
Physical: In children with Sandifer syndrome without mental impairment, the examination findings are normal. Children with Sandifer syndrome with mental impairment often have evidence of spasticity and may be diagnosed with cerebral palsy.
Causes: Dysfunction of the lower esophagus is thought to be the most common precipitating factor. In some children, a cause cannot be found.
Other Problems to be Considered:
Seizures
Tonic seizures
Torticollis
Dystonia
Lab Studies:
Imaging Studies:
Other Tests:
Procedures:
Medical Care: Sandifer syndrome does not require treatment unless the spasms are related to GI causes. In the latter case, therapy should be directed towards the specific cause i.e Gastroesophageal reflux
Consultations:
Diet: When gastroesophageal reflux is discovered, treatment must be directed at the reflux. Please see
Drug Category: Prokinetic agents -- Used to augment cholinergic activity. Prokinetic pharmacotherapy is often used before acid suppression therapy in children without evidence of esophagitis because of the predominance of motility-related problems over increased acid (and regurgitation over pain) in the pathogenesis and presentation.
Metoclopramide (Reglan) -- Dopaminergic antagonist that works by increasing LES tone and gastric emptying. Stimulates muscular activity, leading to decrease in reflux.
Drug Category: Antacids -- Used as diagnostic tool in providing symptomatic relief in infants. Associated benefits include symptomatic alleviation of constipation (aluminium antacids) or loose stools (magnesium antacids). Aluminum hydroxide (ALternaGEL, Amphojel) -- Increases gastric pH above 4 and inhibits proteolytic activity of pepsin, reducing acid indigestion. Antacids can initially be used in mild cases. No effect on frequency of reflux but decreases its acidity.
Drug Category: H2 receptor antagonists -- Like antacids, these agents do not reduce the frequency of reflux, but they decrease the amount of acid in the refluxate by inhibiting acid production. All are equipotent when used in equivalent doses. Work best in patients with nonerosive esophagitis. Because of proton pump inhibitor (PPI) superiority, H2 blockers are reserved for use in patients unable to tolerate PPIs. Cimetidine (Tagamet) -- Inhibits histamine at H2 receptors of gastric parietal cells, resulting in reduced gastric acid secretion, gastric volume, and hydrogen ion concentrations. Ranitidine (Zantac) -- Inhibits histamine stimulation of the H2 receptor in gastric parietal cells, which reduces gastric acid secretion, gastric volume, and hydrogen ion concentrations.
Drug Category: Proton pump inhibitors -- Indicated in patients needing complete acid suppression (eg, infants with chronic respiratory disease or neurologic disabilities). Administer with the first meal of the day (children with nasogastric or gastrostomy tubes may have granules mixed with an acidic juice, then flush tubes to prevent blockage). Omeprazole (Prilosec) -- Decreases gastric acid secretion by inhibiting the parietal cell H+/K+-ATP pump. Used for the short-term treatment (4-8 wk) of GERD.
Prognosis:
Medical/Legal Pitfalls: